Logo image
Back
Induction-phase infliximab monitoring accelerates time to remission in pediatric IBD: a retrospective cohort study
Journal article   Open access   Peer reviewed

Induction-phase infliximab monitoring accelerates time to remission in pediatric IBD: a retrospective cohort study

Nicholas Iovino, Samantha R Paglinco, Mahmoud Abdel-Rasoul, Megan McNicol, Brendan Boyle, Hilary K Michel and Ross M Maltz
Crohn's & colitis 360, v 8(3), otag080
Jul 2026
DOI: https://doi.org/10.1093/crocol/otag080
PMID: 42540636
url
https://doi.org/10.1093/crocol/otag080View
Published, Version of Record (VoR) Open

Abstract

ulcerative colitis infliximab therapeutic drug monitoring biologic Crohn’s disease
In pediatric inflammatory bowel disease (IBD), the optimal timing to begin therapeutic drug monitoring (TDM) of infliximab (IFX) is unclear. We hypothesized that TDM during induction of IFX improves clinical outcomes in children with IBD. This retrospective cohort study utilized data from an internal database at Nationwide Children's Hospital between January 1, 2020, and December 31, 2023. Pediatric IBD patients receiving IFX with induction-phase TDM (I-TDM) at Week 6 were compared to those with maintenance-phase TDM (M-TDM) at Week 14. Propensity score matching (PSM) was used for sex, disease, and age at IFX start. The primary outcome was time to clinical remission. In total, 68 patients were matched from each group. The I-TDM group experienced a shorter median time to clinical remission (140 days [95% CI: 108, 167]) compared to the M-TDM group (203 days [95% CI: 167, 232];  = .006). When adjusting for baseline variations, I-TDM remained independently associated with accelerated clinical remission (aHR = 1.68, 95% CI: 1.10, 2.55;  = .016). While time to therapeutic maintenance IFX levels was similar, post hoc analysis showed that 75% of patients in the I-TDM group achieved target levels in 134 days (95% CI: 114, 182) versus 183 days (95% CI: 153, 224) in the M-TDM group. There were no significant differences in long-term complications between the groups. Induction-phase TDM before the third infusion shortens the time to clinical remission, allowing for more prompt dose adjustments and improving patient outcomes. This approach warrants consideration in clinical practice for children with IBD.

Metrics

1 Record Views

Details

Logo image